Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Immunoprecise Antibodies Ltd (IPA)

Immunoprecise Antibodies Ltd (IPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Light Week for Macroeconomic Figures in U.S. Baystreet - Fri Jul 5, 6:43PM CDT

Monday U.S. Economic Lookahead Consumer Credit (May) Featured Earnings Greenbrier ...

GBX : 65.95 (+2.50%)
IPA : 0.3484 (-9.72%)
AMX : 15.18 (+1.34%)
HELE : 69.06 (+3.38%)
SGH : 20.85 (+0.43%)
WDFC : 278.04 (+0.15%)
PSMT : 88.48 (+0.89%)
AZZ : 95.41 (+8.84%)
PEP : 160.34 (+1.01%)
PRGS : 68.73 (+2.41%)
CTAS : 221.49 (+1.25%)
JPM : 244.76 (+1.65%)
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas Business Wire - Thu Mar 30, 2023

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced a research collaboration...

IPA : 0.3484 (-9.72%)
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology Business Wire - Mon Mar 27, 2023

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), the parent company of BioKey and affiliate of BioStrand, announced today that the EPO has issued a “Decision...

IPA : 0.3484 (-9.72%)
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates Business Wire - Thu Mar 23, 2023

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, is pleased to announce that its wholly...

IPA : 0.3484 (-9.72%)
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 Business Wire - Thu Mar 16, 2023

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal...

IPA : 0.3484 (-9.72%)
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio Business Wire - Wed Mar 15, 2023

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that Talem Therapeutics...

IPA : 0.3484 (-9.72%)
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023 Business Wire - Tue Mar 7, 2023

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss...

IPA : 0.3484 (-9.72%)
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 Business Wire - Thu Dec 15, 2022

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for second quarter fiscal...

IPA : 0.3484 (-9.72%)
IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments Business Wire - Thu Dec 8, 2022

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that its subsidiary, BioStrand BV, has completed...

IPA : 0.3484 (-9.72%)
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022 Business Wire - Mon Dec 5, 2022

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss...

IPA : 0.3484 (-9.72%)

Barchart Exclusives

Up 882% YTD, Is It Too Late to Buy This Fintech Stock? Barchart - 2 minutes ago
A recent guidance boost from DAVE propelled the stock even higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot